🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Moderna's Covid Vaccine for Omicron and the Original Strain Approved in the UK

Published 08/15/2022, 02:10 PM
Updated 08/15/2022, 02:19 PM
© Reuters Moderna's Covid Vaccine for Omicron and the Original Strain Approved in the UK
MRNA
-

By Sam Boughedda

Investing.com - The UK has become the first country in the world to approve Moderna 's (NASDAQ:MRNA) Covid jab that targets the original strain of the virus and the Omicron strain.

It was given the go-ahead by the UK's Medicines and Healthcare products Regulatory Agency after it met the regulator's safety, quality and effectiveness standards.

The jab would be considered another booster dose and is approved for people aged 18 and older. It contains part of the original coronavirus vaccine and part of the Omicron vaccine.

The decision from the MHRA is based on clinical trial data from a phase 2/3 trial, which met all primary endpoints.

"We are delighted with the MHRA's authorization of Spikevax Bivalent Original/Omicron, our next-generation COVID-19 vaccine. This represents the first authorization of an Omicron-containing bivalent vaccine," said Stephane Bancel, Chief Executive Officer of Moderna.

Moderna shares are up 2.5% Monday.

Earlier today, it was revealed that Pfizer (NYSE:PFE) CEO Albert Bourla had tested positive for Covid-19.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.